Literature DB >> 6947119

Increased ammonia production during forearm ischemic work test in McArdle's disease.

K W Rumpf, H Wagner, H Kaiser, H M Meinck, H H Goebel, F Scheler.   

Abstract

A patient with typical features of late onset McArdle's disease is described. During forearm ischemic work test the patient exhibited an exaggerated increase in ammonia release, largely exceeding normal values. It is suggested, that this is due to an activation of the myokinase/myoadenylate deaminase pathway. Besides lack of lactate release increased ammonia release during ischemia may be a typical feature of McArdle's disease.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6947119     DOI： 10.1007/bf01711182

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN： 0023-2173


  8 in total

1.  A metabolic myopathy due to absence of muscle phosphorylase.

Authors:  C M PEARSON; D G RIMER; W F MOMMAERTS
Journal:  Am J Med       Date:  1961-04       Impact factor: 4.965

2.  Myopathy due to a defect in muscle glycogen breakdown.

Authors:  B McARDLE
Journal:  Clin Sci       Date:  1951-02       Impact factor: 6.124

Review 3.  Ammonia production in muscle and other tissues: the purine nucleotide cycle.

Authors:  J M Lowenstein
Journal:  Physiol Rev       Date:  1972-04       Impact factor: 37.312

4.  The second wind phenomenon in McArdle's syndrome.

Authors:  B B Pernow; R J Havel; D B Jennings
Journal:  Acta Med Scand Suppl       Date:  1967

5.  Myoadenylate deaminase deficiency: a new disease of muscle.

Authors:  W N Fishbein; V W Armbrustmacher; J L Griffin
Journal:  Science       Date:  1978-05-05       Impact factor: 47.728

6.  A kinetic determination of ammonia in plasma.

Authors:  H C van Anken; M E Schiphorst
Journal:  Clin Chim Acta       Date:  1974-10-30       Impact factor: 3.786

7.  Adenylate deaminase from rat muscle. Regulation by purine nucleotides and orthophosphate in the presence of 150 mM KCl.

Authors:  T J Wheeler; J M Lowenstein
Journal:  J Biol Chem       Date:  1979-09-25       Impact factor: 5.157

8.  Disruption of the purine nucleotide cycle. A potential explanation for muscle dysfunction in myoadenylate deaminase deficiency.

Authors:  R L Sabina; J L Swain; B M Patten; T Ashizawa; W E O'Brien; E W Holmes
Journal:  J Clin Invest       Date:  1980-12       Impact factor: 14.808
  8 in total
  7 in total

1.  The exercise metaboreflex is maintained in the absence of muscle acidosis: insights from muscle microdialysis in humans with McArdle's disease.

Authors:  J Vissing; D A MacLean; S F Vissing; M Sander; B Saltin; R G Haller
Journal:  J Physiol       Date:  2001-12-01       Impact factor: 5.182

2.  Metabolic profiles of exercise in patients with McArdle disease or mitochondrial myopathy.

Authors:  Nigel F Delaney; Rohit Sharma; Laura Tadvalkar; Clary B Clish; Ronald G Haller; Vamsi K Mootha
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-17       Impact factor: 11.205

Review 3.  Myoadenylate deaminase deficiency.

Authors:  H H Goebel; A Bardosi
Journal:  Klin Wochenschr       Date:  1987-11-02

Review 4.  McArdle's disease with late-onset symptoms: case report and review of the literature.

Authors:  K J Felice; A B Schneebaum; H R Jones
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-05       Impact factor: 10.154

5.  Myoadenylate deaminase deficiency. Functional and metabolic abnormalities associated with disruption of the purine nucleotide cycle.

Authors:  R L Sabina; J L Swain; C W Olanow; W G Bradley; W N Fishbein; S DiMauro; E W Holmes
Journal:  J Clin Invest       Date:  1984-03       Impact factor: 14.808

6.  Excess purine degradation in exercising muscles of patients with glycogen storage disease types V and VII.

Authors:  I Mineo; N Kono; T Shimizu; N Hara; Y Yamada; S Sumi; K Nonaka; S Tarui
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

7.  Myoadenylate deaminase deficiency.

Authors:  H H Goebel; A Bardosi; B Conrad; H D Kuhlendahl; S DiMauro; K W Rumpf
Journal:  Klin Wochenschr       Date:  1986-04-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.